IL234091A - Antiviral compounds, preparations containing them and their use in the treatment of arthritis virus - Google Patents
Antiviral compounds, preparations containing them and their use in the treatment of arthritis virusInfo
- Publication number
- IL234091A IL234091A IL234091A IL23409114A IL234091A IL 234091 A IL234091 A IL 234091A IL 234091 A IL234091 A IL 234091A IL 23409114 A IL23409114 A IL 23409114A IL 234091 A IL234091 A IL 234091A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- antiviral drugs
- arenavirus infection
- arenavirus
- infection
- Prior art date
Links
- 208000005989 Arenaviridae Infections Diseases 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600036P | 2012-02-17 | 2012-02-17 | |
| PCT/US2013/026173 WO2013123215A2 (en) | 2012-02-17 | 2013-02-14 | Antiviral drugs for treatment of arenavirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL234091A0 IL234091A0 (en) | 2014-09-30 |
| IL234091A true IL234091A (en) | 2017-04-30 |
Family
ID=48984889
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL234091A IL234091A (en) | 2012-02-17 | 2014-08-13 | Antiviral compounds, preparations containing them and their use in the treatment of arthritis virus |
| IL251327A IL251327B (en) | 2012-02-17 | 2017-03-22 | Antiviral compounds, preparations containing them and their use for the treatment of Arnavirus infections |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL251327A IL251327B (en) | 2012-02-17 | 2017-03-22 | Antiviral compounds, preparations containing them and their use for the treatment of Arnavirus infections |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9498470B2 (enExample) |
| EP (1) | EP2814486B8 (enExample) |
| JP (1) | JP6200903B2 (enExample) |
| KR (1) | KR101893632B1 (enExample) |
| CN (3) | CN110698408B (enExample) |
| AP (1) | AP3675A (enExample) |
| AU (2) | AU2013221475B2 (enExample) |
| BR (1) | BR112014020345B1 (enExample) |
| CA (1) | CA2864484C (enExample) |
| IL (2) | IL234091A (enExample) |
| MX (1) | MX359989B (enExample) |
| SG (1) | SG11201404898RA (enExample) |
| WO (1) | WO2013123215A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101612179B1 (ko) * | 2013-04-19 | 2016-04-12 | 영남대학교 산학협력단 | 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물 |
| CR20180109A (es) * | 2015-07-20 | 2018-05-03 | Genzyme Corp | Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r) |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| AR117228A1 (es) * | 2018-12-06 | 2021-07-21 | Arisan Therapeutics | DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| JP7677983B2 (ja) | 2020-01-23 | 2025-05-15 | マイオフォルテ セラピューティクス，インク． | Ｐｇｄｈ阻害剤、およびその作製と使用の方法 |
| CN113214161A (zh) * | 2021-02-05 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种具有抗拉沙病毒活性的化合物及其制备方法和应用 |
| CN113234022A (zh) * | 2021-02-05 | 2021-08-10 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种苯并咪唑类衍生物及其合成方法和应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| WO2023009618A1 (en) * | 2021-07-28 | 2023-02-02 | Epirium Bio, Inc. | Bicyclic pgdh inhibitors and methods of making and using |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN116217490B (zh) * | 2023-02-03 | 2025-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种苯并咪唑类化合物及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63157157A (ja) * | 1986-12-22 | 1988-06-30 | Canon Inc | 電子写真感光体 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| DE3928177A1 (de) * | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPH0446352A (ja) * | 1990-06-14 | 1992-02-17 | Minolta Camera Co Ltd | 感光体 |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| AU7275894A (en) * | 1993-08-04 | 1995-02-28 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazolylalkylamine derivative and pharmaceutical composition thereof |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| IL150150A0 (en) * | 2000-01-14 | 2002-12-01 | Schering Ag | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| US7863310B2 (en) * | 2004-02-03 | 2011-01-04 | Eli Lilly And Company | Kinase inhibitors |
| DE102005012875B4 (de) * | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
| EP1988776B1 (en) | 2006-03-02 | 2012-08-08 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| US7977365B2 (en) * | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| CA2672290A1 (en) * | 2007-01-15 | 2008-07-24 | The United States Of America, As Represented By The Secretary Of The Arm Y, On Behalf Of The U.S. Army Research Institute Of Infectious Diseases | Antiviral compounds and methods of using thereof |
| CA2698075C (en) * | 2007-08-27 | 2016-04-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| WO2010030360A1 (en) * | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| JP2012512223A (ja) * | 2008-12-18 | 2012-05-31 | エフ．ホフマン−ラ ロシュ アーゲー | チアゾリル−ベンズイミダゾール類 |
| WO2011063293A1 (en) * | 2009-11-20 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antihelminth agents |
-
2013
- 2013-02-14 MX MX2014009931A patent/MX359989B/es active IP Right Grant
- 2013-02-14 BR BR112014020345-8A patent/BR112014020345B1/pt not_active IP Right Cessation
- 2013-02-14 CN CN201910977855.2A patent/CN110698408B/zh not_active Expired - Fee Related
- 2013-02-14 JP JP2014557773A patent/JP6200903B2/ja not_active Expired - Fee Related
- 2013-02-14 CA CA2864484A patent/CA2864484C/en active Active
- 2013-02-14 SG SG11201404898RA patent/SG11201404898RA/en unknown
- 2013-02-14 US US14/379,028 patent/US9498470B2/en active Active
- 2013-02-14 EP EP13749809.3A patent/EP2814486B8/en active Active
- 2013-02-14 AU AU2013221475A patent/AU2013221475B2/en not_active Ceased
- 2013-02-14 AP AP2014007925A patent/AP3675A/xx active
- 2013-02-14 CN CN201380019936.2A patent/CN104507473A/zh active Pending
- 2013-02-14 KR KR1020147025954A patent/KR101893632B1/ko not_active Expired - Fee Related
- 2013-02-14 WO PCT/US2013/026173 patent/WO2013123215A2/en not_active Ceased
- 2013-02-14 CN CN201910977868.XA patent/CN110776453A/zh active Pending
-
2014
- 2014-08-13 IL IL234091A patent/IL234091A/en active IP Right Grant
-
2016
- 2016-11-16 US US15/353,351 patent/US10000486B2/en active Active
-
2017
- 2017-01-18 AU AU2017200346A patent/AU2017200346B2/en not_active Ceased
- 2017-03-22 IL IL251327A patent/IL251327B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251327A0 (en) | Antiviral compounds, preparations containing them and their use for the treatment of arnovirus infections | |
| IL235062A0 (en) | Compounds and methods for antiviral therapy | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| IL236504A0 (en) | Oligonucleotide for the treatment of muscular dystrophy patients | |
| ZA201405898B (en) | Devices for targeted delivery of therapeutic implants | |
| GB201213087D0 (en) | Inhibition of HIV-1 infection | |
| GB201217097D0 (en) | Treatment of bacterial infection | |
| EP2291184A4 (en) | ANTIVIRAL DRUGS FOR THE TREATMENT OF ARENAVIRUS INFECTIONS | |
| PL2644215T3 (pl) | Aparat do pozaustrojowej obróbki krwi | |
| HUE039650T2 (hu) | Rendszer gyógykezeléshez | |
| SMT201900282T1 (it) | Composizione farmaceutica per il trattamento delle infezioni da hiv | |
| GB201207543D0 (en) | Treatment of transfusion blood | |
| PL2846806T3 (pl) | Leczenie depresji oddechowej | |
| GB201207907D0 (en) | Treatment of depression | |
| EP2869796A4 (en) | PATIENT TREATMENT SYSTEM | |
| GB201217990D0 (en) | Antiviral drug derivatives | |
| HUP1200530A2 (en) | Medical splint | |
| GB201204645D0 (en) | Treatment of disease | |
| GB201208505D0 (en) | Treatment of skin condition | |
| GB201208503D0 (en) | Treatment of a skin condition | |
| EP2854878A4 (en) | MEDICAL DEVICE FOR TREATING WOUNDS | |
| GB201207476D0 (en) | pharmaceutical for the treatment of leishmaniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |